Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up

Haematologica
Ute HegenbartStefan O Schönland

Abstract

Chemotherapy in light chain amyloidosis aims to normalize the involved free light chain in serum, which leads to an improvement, or at least stabilization of organ function in most responding patients. We performed a prospective single center phase 2 trial with 50 untreated patients not eligible for high-dose treatment. The treatment schedule comprised 6 cycles of oral lenalidomide, melphalan and dexamethasone every 4 weeks. After 6 months, complete remission was achieved in 9 patients (18%), very good partial remission in 16 (32%) and partial response in 9 (18%). Overall, organ response was observed in 24 patients (48%). Hematologic and cardiac toxicities were predominant adverse events. Mortality at 3 months was low at 4% (n=2) despite the inclusion of 36% of patients (n=18) with cardiac stage Mayo 3. After a median follow-up of 50 months, median overall and event-free survival were 67.5 months and 25.1 months, respectively. We conclude that the treatment of lenalidomide, melphalan and dexamethasone is very effective in achieving a hematologic remission, organ response and, consecutively, a long survival in transplant ineligible patients with light chain amyloidosis. However, as toxicity and tolerability are the major problem...Continue Reading

Citations

Dec 10, 2017·Hematology·Giampaolo Merlini
Sep 1, 2018·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Krzysztof BatkoKatarzyna Krzanowska
Oct 28, 2019·Blood Advances·Efstathios KastritisMeletios A Dimopoulos
Jan 28, 2020·British Journal of Haematology·Oliver C CohenAshutosh D Wechalekar
Oct 21, 2019·Clinical Research in Cardiology : Official Journal of the German Cardiac Society·Michael M KreusserPhilip W Raake
Apr 10, 2020·Leukemia·Oliver C Cohen, Ashutosh D Wechalekar
May 13, 2020·Current Hematologic Malignancy Reports·Joselle CookRahma Warsame
Jan 22, 2019·Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis·Efstathios KastritisMeletios A Dimopoulos
Oct 27, 2018·Nature Reviews. Disease Primers·Giampaolo MerliniMorie A Gertz
May 26, 2020·Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis·Paolo MilaniUte Hegenbart
Sep 20, 2018·F1000Research·Talha BadarParameswaran Hari
Oct 13, 2020·Expert Opinion on Pharmacotherapy·R SpoladoreG Fragasso
Feb 16, 2021·Expert Opinion on Drug Safety·Mario NuvoloneGiovanni Palladini
Jun 6, 2021·ESC Heart Failure·Robert Daniel AdamRuxandra Jurcuţ
May 17, 2021·Blood Cancer Journal·M Hasib Sidiqi, Morie A Gertz
Jun 12, 2020·Acta Haematologica·Layla Van Doren, Suzanne Lentzsch
May 1, 2020·Acta Haematologica·Paolo Milani, Giovanni Palladini

❮ Previous
Next ❯

Methods Mentioned

BETA
cytogenetic aberrations
iFISH

Software Mentioned

R

Related Concepts

Related Feeds

Cardiotoxicity

Cardiotoxicity refers to the muscle damage or dysfunction of heart electrophysiology caused by drug intake or due to disease complications. It is a well-known side effect of several cytotoxic drugs, especially of the anthracyclines and can lead to long term morbidity. Here is the latest research.